Enliven Therapeutics to Share Key Findings at SOHO 2025 Annual Meeting in Houston

Enliven Therapeutics to Present at SOHO 2025 Annual Meeting

Enliven Therapeutics, Inc., a biopharmaceutical company focused on developing small molecule therapeutics, has announced an upcoming presentation at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting in Houston, Texas, from September 3-6, 2025. The company aims to showcase findings from its ENABLE Phase 1a/1b clinical trial concerning ELVN-001, a selective active site inhibitor targeting chronic myeloid leukemia (CML).

The presentation will feature two formats: an oral session and a poster session. Dr. Michael J. Mauro, a respected figure in the field, will lead the discussions. The poster session is set for September 3rd at 6:25 PM CDT, located in Hall B3, Level 3, under poster number CML-575. The oral presentation will follow on September 4th during the Chronic Myeloid Leukemia oral session, scheduled for 11:40 AM – 11:50 AM CDT.

These sessions will highlight findings that were initially shared at the European Hematology Association (EHA) Congress earlier this year, emphasizing Enliven's commitment to transparency and collaboration in research.

About the ENABLE Study

The ENABLE study focuses on evaluating ELVN-001 in patients with CML who have received prior treatments. This study examines the therapeutic potential of this innovative compound to improve outcomes in chronic myeloid leukemia, a cancer of the blood and bone marrow that can lead to severe health issues if left unchecked.

The study's design allows for a thorough investigation of the drug's efficacy and safety profile, making it a critical component for clinicians looking for better therapy options for their patients. The results from this research could pave the way for more effective treatments, thereby enhancing the quality of life for individuals battling this challenging disease.

Enliven’s Mission and Future Aspirations

Enliven Therapeutics operates with the mission of not only extending life but also improving health quality through precision oncology. As a clinical-stage company, Enliven aims to address both existing and emerging unmet medical needs by leveraging a data-driven approach in drug discovery and development. The integration of clinically validated biological targets with innovative chemistry aims to craft therapies that are potentially first-in-class or best-in-class.

The company is based in Boulder, Colorado, and is dedicated to enhancing the well-being of patients through its research and development efforts. Enliven is keen to advance its candidates through clinical stages to regulatory approvals and ultimately successful commercialization.

According to reports, the results presented during SOHO 2025 are anticipated to receive significant attention from the oncological community, further solidifying Enliven's position as a forerunner in biopharmaceutical innovations for cancer treatment. The presentations will be accessible after the event on Enliven's official website in the "Program Presentations & Publications" section, providing ongoing transparency and updates for interested stakeholders.

As the date approaches, the excitement around the findings from the ENABLE study continues to grow, underscoring Enliven Therapeutics’ commitment to innovative solutions in the fight against chronic myeloid leukemia and similar challenges in oncology.